InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,226.59
(
0.07%
)
US TECH 100
17,733.80
(
0.29%
)
Dow Jones
39,572.37
(
0.15%
)
Brent Oil
83.48
(
1.32%
)
Bitcoin
62,841.86
(
2.27%
)
Post# of 234
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

mark27

Send PM Follow Ignore
Followers 88
Posts 8395
Boards Moderated 0
Alias Born 08/24/2007

mark27

Re: MONEYMADE post# 230

Saturday, 06/06/2009 11:54:23 AM

Saturday, June 06, 2009 11:54:23 AM

Post# of 234
The shareholders will benefit from the sale of the MEDI contract and the trodusquemine and Squalamine patents and research. There is good value in all. MEDI may buy back the contract for $10million or $20 million. The contract stipulates that GENR shareholders receive $54million in timeline payments..and 10% royalty from eventual marketing of the IL9 drug.

The vote was no suprise to anyone... and it benefits shareholders who will end up owning all assets.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up